HACKENSACK, NJ - Champions Oncology , Inc. (NASDAQ:CSBR), a research organization specializing in oncology with a focus on technology-enabled testing services, has announced the expansion of its bioanalytical services with new technology and leadership. The company has integrated several Cytek Aurora flow cytometers into its portfolio and appointed Troy Tremaine, MBA, as the new head of Bioanalytical Commercial Strategy.
The integration of Cytek Aurora technology is set to enhance the company's existing spectral and conventional flow cytometry capabilities, allowing for more complex spectral analysis. This strategic move is expected to better serve Champions Oncology's clients by offering more in-depth analytical services. The company's CEO, Ronnie Morris, expressed excitement over the advancements, stating that the new instruments will improve their competitive edge in a large market.
Troy Tremaine, with his decades of experience in commercial leadership across various therapeutic areas within the preclinical and bioanalytical sector, is anticipated to drive the commercial strategy for this expanding segment of the company's services.
Champions Oncology provides comprehensive research services in preclinical and clinical settings, specializing in oncology drug discovery and development. It boasts the largest bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, which facilitates the delivery of high-quality data to biopharmaceutical organizations globally. The company's investments in bioanalytical platforms and data analytics aim to support the advancement of oncology therapeutics.
The information for this report is based on a press release statement from Champions Oncology, Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.